Business / Biotech

Sarepta Therapeutics Announces Workforce Reduction and Strategic Shift

Sarepta Therapeutics recently announced a significant restructuring, including laying off approximately one-third of its workforce. This decision follows restrictions placed on the company's gene therapy for Duchenne muscular dystrophy afte...

Jul 16, 2025 21:01 Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move

Sarepta Therapeutics Announces Workforce Reduction and Strategic Shift

Image via STAT

TOPIC sarepta

Finance / Stock Market

Sarepta Therapeutics (SRPT) Stock Analysis: Analyst Ratings and Market Sentiment

Sarepta Therapeutics (SRPT) is a medical research and drug development company focused on precision genetic medicines for rare diseases. Recent analyst ratings and options market activity provide insights into the stock's potential.

Jul 16, 2025 21:01 JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating

Biotech / Gene Therapy

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety

Sarepta Therapeutics is taking proactive steps to address safety concerns regarding ELEVIDYS, its gene therapy for Duchenne muscular dystrophy, following reports of acute liver failure in non-ambulatory patients. The company is working with...

Jun 16, 2025 12:32 Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne